
Superpower peptides available for pre-order. Get first access.

Peptide science
What have ARA-290 neuropathy trials shown?
ARA-290 neuropathy trials were small Phase II studies in sarcoidosis and type 2 diabetes. See the pain and corneal nerve results and why no Phase III exists.
Quick answer
ARA-290's neuropathy research is Phase II only. Small placebo-controlled trials enrolled 22 to 64 people with sarcoidosis small-fiber neuropathy or type 2 diabetes. These trials reported better symptom scores and, in some, more corneal nerve fibers after 28 days. Pain also eased in placebo groups. No Phase III trial has been completed, and ARA-290 is not approved for neuropathy.
- Published
- November 11, 2026
- Last updated
- November 11, 2026
What ARA-290 neuropathy trials have shown so far
ARA-290 neuropathy research comes from small Phase II trials in people with sarcoidosis-related small-fiber neuropathy or type 2 diabetes1, which reported better symptom scores. In some trials, 28 days of dosing was followed by more nerve fibers in the eye's cornea2. No Phase III trial has been completed.
ARA-290, also called cibinetide, is an 11-amino-acid peptide modeled on part of erythropoietin. In laboratory and animal studies, the peptide did not stimulate red blood cell production3. Small-fiber neuropathy is damage to the body's thinnest nerve fibers4, which carry pain and temperature signals5. ARA-290's nerve pain trials began in people with sarcoidosis.
ARA-290 trials in sarcoidosis small-fiber neuropathy
Three small placebo-controlled trials in sarcoidosis-related small-fiber neuropathy linked ARA-290 to better symptom scores, more corneal nerve fibers, or both. In two of those trials, pain scores improved in the placebo groups too. Small-fiber neuropathy is common in sarcoidosis, causes pain and tingling, and often resists standard immunosuppressive therapy6.
Alongside symptom questionnaires, some trials tested temperature sensation, an objective check used to identify small-fiber neuropathy7. The two later trials added corneal confocal microscopy, a quick, noninvasive eye scan. The scan images small sensory nerves in the cornea8, which resemble those in skin.
| Trial | Participants | Design | Duration | Key result |
| 2012 pilot | 22 (12 ARA-290, 10 placebo) | Randomized, double-blind, placebo-controlled; 2 mg intravenous, 3 times weekly | 4 weeks | Symptom checklist improved more than placebo9 (11.5 vs 2.9 points); pain scores improved equally in both groups |
| 2013 trial | 38 enrolled (21 ARA-290, 17 placebo) | Blinded, placebo-controlled; 4 mg subcutaneous, daily | 28 days, follow-up to 16 weeks | Better symptom scores, more corneal nerve fibers2, changes in temperature sensitivity, and a longer 6-minute walk |
| 2017 Phase IIb | 64 | Randomized, placebo-controlled, dose-ranging; 1, 4, or 8 mg subcutaneous, daily; 2 sites10 | 28 days | Only the 4 mg dose significantly increased corneal nerve fiber area11 (697 µm² over placebo, P=0.012); pain eased in every group, including placebo |
The Phase IIb trial also found more regenerating nerve fibers in skin biopsies11 at the middle dose. The corneal gains in that trial tracked with six-minute walk distance. The 22-person pilot was exploratory, so its effect sizes are imprecise. ARA-290's type 2 diabetes trial measured corneal nerve fibers too.
ARA-290 trials in people with type 2 diabetes
Two small studies in people with diabetes, mostly type 2, have tested ARA-290, with better neuropathy symptom scores in one and no improvement in vision in the other. Nerve damage may affect at least 10% to 15% of people5 newly diagnosed with type 2 diabetes. That share rises to 50% after 10 years5.
The neuropathy trial enrolled 49 people with painful diabetic neuropathy and analyzed 48. Participants self-injected 4 mg of ARA-290 or placebo12 under the skin daily for 28 days. PainDetect scores improved in the ARA-290 group12. PainDetect is a questionnaire that screens for nerve-type pain13.
Corneal nerve fiber density rose only in participants whose starting density was below the normal range, a subgroup chosen after the trial ended12. On placebo, density did not change. Lower corneal nerve density is a recognized feature of diabetic neuropathy14.
Average blood sugar, measured as HbA1c, and lipid levels also improved over the 56-day study12, though the authors called the HbA1c change small. The authors concluded that ARA-290 deserves continued clinical evaluation.
A single-center Phase II study enrolled nine people with diabetic macular edema, swelling in the center of the retina. Eight completed 12 weeks of ARA-290 at the neuropathy trial's daily dose. Mean visual acuity and central retinal thickness15 did not improve. With descriptive results only, the study supports no efficacy conclusion.
The study, registered as open-label, was terminated after the study drug expired with no replacement16. Like the sarcoidosis trials, both diabetes studies were small and short.
What the ARA-290 neuropathy evidence cannot show
The ARA-290 neuropathy evidence cannot show a lasting benefit, because every trial was Phase II or smaller, enrolled 64 people or fewer, and dosed participants for 4 to 12 weeks. The trials' own investigators have called for longer dosing and follow-up1. Phase II studies check whether a drug seems to work but are not large enough to show patient benefit17. Phase III trials enroll 300 to 3,000 people17 to answer that question.
As of November 2026, ClinicalTrials.gov lists no Phase III or recruiting ARA-290 neuropathy trial. The most advanced one listed is the completed 64-person Phase IIb10.
Corneal nerve counts are surrogate endpoints11, so more fibers do not by themselves mean less pain or better function. In people with sarcoidosis and chronic pain, corneal scan findings did not match skin biopsies18.
No ARA-290 trial in people with sciatica appears on ClinicalTrials.gov as of November 2026. ARA-290's sciatic nerve research comes from mice with sciatic nerve injury1, where it eased pain-like sensitivity.
Each human trial also recorded ARA-290 side effects. Results this early are easier to weigh with reliable information on peptides.
Where can I learn about peptides?
Small Phase II trials such as ARA-290's are easy to overread, so knowing a study's size, design, and phase matters. Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians.
ARA-290 began as a short fragment of a much larger protein. The science behind peptides explains how short chains of amino acids are built, named, and studied.
IMPORTANT SAFETY INFORMATION
ARA-290 (cibinetide) is NOT FDA-approved for any indication. It is not legally marketed for human use. Superpower Health does not prescribe, sell, compound, or facilitate access to ARA-290. This page is provided for educational purposes only and does not constitute medical advice.
Clinical safety data come from small Phase II trials lasting 12 weeks at most. In the type 2 diabetes trial, researchers judged two serious adverse events possibly related to ARA-290. Longer-term safety has not been characterized.
ARA-290 should not be used by anyone outside an IRB-approved clinical research study. No approved label exists, so no formal contraindications exist. Populations of particular concern, based on the compound's proposed mechanism and the absence of human data, include: individuals with current or recent cancer (theoretical cell-survival signaling effects); pregnant or breastfeeding individuals (no human data exist); and individuals with reduced kidney function (one trial participant's pre-existing kidney impairment worsened during dosing). These are illustrative concerns, not a contraindication checklist.
Products sold online as ARA-290 or cibinetide are unregulated and often labeled "for research use only." Their identity, purity, and dosing have not been verified by the FDA or any independent regulatory authority. There is no legal pharmaceutical-grade source for ARA-290 in the United States.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to ARA-290. ARA-290 is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.